Allflex Livestock Intelligence Continues its Commitment with the Nestlé Dairy Farming Institute to Advance Dairy Sector in China

SHUANGCHENG, CHINA, October 31, 2019 – Allflex Livestock Intelligence today announced its continued commitment to the Nestlé Dairy Farming Institute, a world-class training center, in Shuangcheng, Heilongjiang Province in Northeast China, on the Institute’s fifth anniversary. The facility is known to be among one of the largest investments in the dairy industry, which has helped to modernize Chinese dairy farming practices.

“We have a long-standing relationship with Nestlé, established in 2014, when Allflex Livestock Intelligence was selected to lead the cow monitoring and welfare aspects of the Dairy Farming Institute in China,” said Jeroen van de Ven, Chief Operating Officer, Allflex Livestock Intelligence.

“As milk is an essential part of the Chinese diet, we continue to partner with the Institute to help establish a reliable source of high-quality milk for processing facilities throughout China,” said Ian Lahiffe, Managing Director, Allflex Livestock Intelligence in China. “We also are confident that our contribution will be significant in helping Chinese farmers increase production efficiency, advancing the dairy sector in China to the next level of development in a sustainable and efficient way.”

The Dairy Farming Institute includes classrooms, laboratories, dormitories and training farms for instructors, students, farm managers and professionals within the dairy industry, accommodating more than 1,000 individuals in 17 different course offerings. In the Institute’s curriculum and hands-on training practices, farmers and dairy industry professionals can develop the skills to manage larger, more sophisticated dairy operations, including animal health and well-being, milking hygiene, animal nutrition and socio-economic management.

About Allflex Livestock Intelligence   

Allflex Livestock Intelligence is a world leader in the design, development, manufacturing and delivery of solutions for animal identification, monitoring and traceability. Our data-driven solutions are used by farmers, companies and countries to manage hundreds of millions of animals worldwide. By putting intelligent, actionable management information into farmers’ hands, our solutions empower them to act in a timely manner to safeguard their animals’ health and wellbeing, while achieving optimal production outcomes for a healthy food supply. Allflex Livestock Intelligence is a Livestock portfolio of digital products within MSD Animal Health.

As the largest provider of animal identification technology, we meet growing customer needs by providing over 500 million tags for identifying, tracking and monitoring animals every year and we monitor over 5.5 million cows daily, which allows access to real-time, actionable data and insights to help improve or enhance animal management and health outcomes.

With over 60 years of experience and around 1,900 team members worldwide, we have a global network of experts, each with a great depth of experience and unparalleled knowledge, who provide a valuable resource to farmers, companies and countries. Allflex Livestock Intelligence has manufacturing and technology subsidiaries in North America, Europe, Israel, South America, China, Australia and New Zealand. Our products are distributed in over 100 countries.Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. 

For more information, visit https://www.allflex.global.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).